Skip to main content

Advertisement

SpringerLink
Log in

Management of hereditary breast and ovarian cancer

  • Invited Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Hereditary breast and ovarian cancer (HBOC) syndrome represents 5−10% of all breast cancers. In Japan, the HBOC syndrome is frequently diagnosed in patients with breast cancer. Therefore, a treatment strategy combining a plan for existing breast cancer and for reduction of future breast and ovarian cancer risk is necessary. Breast cancer risk-reducing management involves three options—surveillance, chemoprevention, and risk-reducing mastectomy (RRM). RRM can prevent >90% of new breast cancers. Ovarian cancer risk management options are more limited, and risk-reduction salpingo-oophorectomy is the only option since there is no proven effective early detection method available. The local recurrence rate following breast-conserving surgery in BRCA1/2 mutation-associated breast cancer is not significantly higher than that in sporadic breast cancer. Furthermore, there is no difference in prognosis between surgical methods. Clinicians should inform patients that there are no data on long-term monitoring and fully discuss risks of re-developing breast cancer with patients when choosing the surgical method. In HBOC, BRCA1/2 mutations lead to failure of double-strand DNA break repair, with poly ADP-ribose polymerase (PARP) playing an important role in single-strand DNA nick repair. Use of PARP inhibitors in HBOC prevents DNA repair (synthetic lethality) leading to cell death. This review summarizes management of the HBOC syndrome based on recent evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ford D et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695. https://doi.org/10.1016/S0140-6736(94)91578-4

    Article  CAS  PubMed  Google Scholar 

  2. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689. https://doi.org/10.1086/301749

  3. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271. https://doi.org/10.1002/ajmg.1320560305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kasner E, Hunter CA, Ph D et al (2013) NIH public access 70:646–656. https://doi.org/10.1002/ana.22528.Toll-like

    Google Scholar 

  5. Valachis A, Nearchou AD, Lind P (2014) Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-014-2890-1

    PubMed  Google Scholar 

  6. Graeser MK, Engel C, Rhiem K et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. https://doi.org/10.1200/JCO.2008.19.9430

    PubMed  Google Scholar 

  7. Metcalfe K, Gershman S, Lynch HT et al (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. https://doi.org/10.1038/bjc.2011.120

    Google Scholar 

  8. NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) genetic/familial high-risk assecessment: breast and ovarian version 2. 2017, pp 1–77

  9. Pijpe A, Andrieu N, Easton DF et al (2012) Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 345:e5660. https://doi.org/10.1136/bmj.e5660

    Article  PubMed  PubMed Central  Google Scholar 

  10. Breast E, Trialists C, Group C (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351:1451–1467

    Article  Google Scholar 

  11. King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. https://doi.org/10.1001/jama.286.18.2251

    Google Scholar 

  12. Cauley JA, Norton L, Lippman ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. https://doi.org/10.1023/A:1006478317173

    PubMed  Google Scholar 

  13. Martino S, Cauley JA, Barrett-Connor E et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djh319

    PubMed  Google Scholar 

  14. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. https://doi.org/10.1001/jama.295.23.joc60074

    Google Scholar 

  15. Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM et al (2015) Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. https://doi.org/10.1002/ijc.29032

    PubMed  Google Scholar 

  16. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djn442

    PubMed  PubMed Central  Google Scholar 

  17. Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Finch APM, Lubinski J, Møller P et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547–1553. https://doi.org/10.1200/JCO.2013.53.2820

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zakhour M, Danovitch Y, Lester J et al (2016) Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2016.08.336

    Google Scholar 

  20. Yamauchi H (2016) Merits and demerits of practice for hereditary breast and ovarian cancer syndrome (advices and issues). In: Toi M, Winer E, Benson J, Klimberg S (eds) Personalized treatment of breast cancer. Springer Japan, Tokyo, pp 33–45. https://doi.org/10.1007/978-4-431-55552-0_3

    Google Scholar 

  21. Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. https://doi.org/10.1093/jnci/91.17.1475

    Google Scholar 

  22. Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622. https://doi.org/10.1056/NEJMoa012158

    Article  PubMed  Google Scholar 

  23. Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. https://doi.org/10.1056/NEJMoa020119

    PubMed  Google Scholar 

  24. Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. https://doi.org/10.1001/jama.296.2.185

    PubMed  Google Scholar 

  25. Kramer JL, Velazquez IA, Chen BE et al (2005) Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23:8629–8635. https://doi.org/10.1200/JCO.2005.02.9199

    Article  PubMed  Google Scholar 

  26. Domchek S, Friebel T, Neuhausen S (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(06)70585-X

    Google Scholar 

  27. Chang-Claude J, Andrieu N, Rookus M et al (2007) Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-06-0829

    Google Scholar 

  28. Eisen A, Lubinski J, Klijn J et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. https://doi.org/10.1200/JCO.2004.00.7138

    Google Scholar 

  29. Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. https://doi.org/10.1200/JCO.2007.13.9626

    PubMed Central  Google Scholar 

  30. Giusti RM, Rutter JL, Duray PH et al (2003) A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet. https://doi.org/10.1136/jmg.40.10.787

    PubMed  PubMed Central  Google Scholar 

  31. Heemskerk-Gerritsen BAM, Seynaeve C, Van Asperen CJ et al (2015) Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv033

    PubMed Central  Google Scholar 

  32. Robson ME, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. https://doi.org/10.1186/bcr.658

    PubMed  Google Scholar 

  33. Kirova YM, Stoppa-Lyonnet D, Savignoni A et al (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41:2304–2311. https://doi.org/10.1016/j.ejca.2005.02.037

    Article  PubMed  Google Scholar 

  34. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C et al (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867–876. https://doi.org/10.1016/J.EJCA.2006.12.009

    Article  CAS  PubMed  Google Scholar 

  35. Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2005.02.7888

    Google Scholar 

  36. Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early onset breast cancer by BRCA1/2 status. Lancet. https://doi.org/10.1016/S0140-6736(02)08434-9

    PubMed  Google Scholar 

  37. Pierce LJ, Phillips KA, Griffith KA et al (2010) Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-010-0894-z

    Google Scholar 

  38. Bernier J, Poortmans P (2015) Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review. Breast 24:100–106. https://doi.org/10.1016/j.breast.2014.12.003

    Article  PubMed  Google Scholar 

  39. Templeton AJ, Gonzalez LD, Vera-Badillo FE et al (2016) Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: a systematic review and meta-regression. PLoS One. https://doi.org/10.1371/journal.pone.0154789

    Google Scholar 

  40. Arun B, Bayraktar S, Liu DD et al (2011) Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. https://doi.org/10.1200/JCO.2011.35.2682

    PubMed  PubMed Central  Google Scholar 

  41. Narod SA, Metcalfe K, Lynch HT et al (2013) Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat. https://doi.org/10.1007/s10549-013-2429-x

    PubMed Central  Google Scholar 

  42. Chabalier C, Lamare C, Racca C et al (2006) BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. https://doi.org/10.4161/cc.5.9.2726

    PubMed  Google Scholar 

  43. Zhou C, Smith JL, Liu J (2003) Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene. https://doi.org/10.1038/sj.onc.1206319

    Google Scholar 

  44. Byrski T, Gronwald J, Huzarski T et al (2010) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. https://doi.org/10.1200/JCO.2008.20.7019

    PubMed  Google Scholar 

  45. Schreiber V, Dantzer F, Ame J-C et al (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. https://doi.org/10.1038/nrm1963

    PubMed  Google Scholar 

  46. Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. https://doi.org/10.1016/s1470-2045(11)70214-5

    PubMed  Google Scholar 

  47. Robson ME, Im S-A, Senkus E et al (2017) OlympiAD: phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). J Clin Oncol 35:LBA4. https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA4

    Article  Google Scholar 

  48. Tutt ANJ, Kaufman B, Gelber RD et al OlympiA: a randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). ASCO Meet Abstr 2015

  49. Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(17)30469-2

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgical Oncology, St. Luke’s Internation Hospital, Tokyo, Japan

    Hideko Yamauchi & Junko Takei

Authors
  1. Hideko Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junko Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideko Yamauchi.

Ethics declarations

Conflict of interest

Hideko Yamauchi received lecture fees from Taiho Pharma.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamauchi, H., Takei, J. Management of hereditary breast and ovarian cancer. Int J Clin Oncol 23, 45–51 (2018). https://doi.org/10.1007/s10147-017-1208-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1208-9

Keywords

Search

Navigation